News
Academy
Publications
All PublicationsE-Books
Media
Editorial PodcastsEditorial VideosPeer ExchangePractice AcademySponsored PodcastsSponsored Videos
More
Conferences
Conference CoverageConference Listing
Columns
All ColumnsA Closing ThoughtClinical Trial InsightsView from BrusselsView from Washington
Resources
AdvertiseBlogsEventsFront & CenterPartner PerspectivesWhite Papers
Webcasts

Subscribe

  • News
  • Academy
  • Publications
  • Media
  • Conferences
  • Columns
  • Resources
  • Webcasts
  • Subscribe
  • Clinical Operations & Strategy
    • Decentralized Clinical Trials
    • Trial Design
    • Investigative Sites
    • CRO/Sponsor
    • Risk-Based Monitoring
    • Protocol Design
    • Clinical Trial Supply Chain
    • Study Start-Up
    • Early Phase Development
  • DEI
    • Industry Initiatives
    • Diversity Action Plans
    • Recruitment
  • Data Management
    • Analytics
    • Electronic Data Capture
    • Real World Evidence
    • Metrics & Benchmarks
  • Patient Participation
    • Integrated Research
    • CRAACO
    • Enrollment
  • Regulatory
    • Institutional Review Board & Ethics Committee
    • FDA
    • EMA
  • Technology
    • Artificial Intelligence/Machine Learning
    • eClinical
    • mHealth
Spotlight -
CNS Drug Development Resources|
Conference Coverage|
Peer Exchange|
DE&I|
Editorial Videos
Advertisement

Pierre Geoffroy

Advertisement

Articles by Pierre Geoffroy

i2-813762-1408538034170.gif

CNS Drug Liabilities in Early Phase Clinical Trials

ByPierre Geoffroy
May 1st 2013

Only eight percent of CNS drugs will reach approval, in part because of the high adverse effects standards.

Advertisement

Latest Updated Articles

  • i2-813762-1408538034170.gif
    CNS Drug Liabilities in Early Phase Clinical Trials

    Published: May 1st 2013 | Updated:



Advertisement
Advertisement

Trending on Applied Clinical Trials Online

1

Honing the Power of AI for Next Generation Trial Oversight and Execution

2

AstraZeneca’s Phase III POTOMAC Trial Shows Imfinzi Significantly Improves Disease-Free Survival in High-Risk NMIBC

3

Verzenio and Kisqali Deliver Positive Long-Term Results in Early Breast Cancer Trials

4

Accelerating Development Through Parallel Execution and Rigorous Quality Controls

5

The Value of Pragmatic Randomized Clinical Trials: Strategic Approaches for Real-World Impact

  • About
  • Advertise
  • Contact Us
  • Editorial Contacts
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Applied Clinical Trials
  • BioPharm International
  • Cannabis Science and Technology
  • Chromatography Online
  • Nutritional Outlook
  • Pharmaceutical Commerce
  • Pharmaceutical Executive
  • Pharm Tech
  • Spectroscopy Online
  • Turbo Machinery Magazine
IS1
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us